Spain’s Grifols to buy U.S.-based Talecris Biotherapeutics for $3.4 bln

Spain’s Grifols has agreed to buy U.S.-based Talecris Biotherapeutics, which makes plasma-based protein therapies, for $3.4 billion in a bold move to expand its business in blood products – Reuters

Be the first to comment

Leave a Reply

Your email address will not be published.


*